Original Article

Effects of Depression Screening on Quality of Life after Diagnosis of Acute Coronary Syndrome, Single Center Experience

Depression Screening on Quality of Life

Abubakr Ali Saad[1], Munir Ahmed Rashid[1], Saima Dastgeer[2], Zahid Iqbal[1], Muhammad Hussan Raza[1] and Imran Javaid[1]

ABSTRACT

Objective: To verify whether analytically finding depression in survivors of an ACS increases the standard of life and depression compared to the accustomed concern.

Study Design: Randomized controlled trial study.

Place and Duration of Study: This study was conducted at the DG Khan Medical College, DG Khan from September 03 2021 to 02 March 2022.

Materials and Methods: 450 ACS patients were enrolled. ACS patients who had been admitted to the hospital in the past 2 to 12 months without a prior history of depression were eligible for the study. The analyses were conducted based on intention-to-treat.

Results: Patients with ACS received (1) systematic depression screening utilizing the eight-item Patient Health Questionnaire, with notification of crucial care physicians and stipulation of centralized, patient-performed, gradual depression care for those with depression, Patients with a positive screening result (8-Item Patient Health Questionnaire score >10: Screen, notify, and treat); 2) systematic depression screening with notification of primary healthcare providers for those with a positive finding result (Screen and notify); and (3) normal care with no finding. A quality attuned life-year change was the crucial upshot. The second effect was the number of days with no depression. Patients' interviews and hospital minutes were used to evaluate adverse effects and death.

Conclusion: Organized depression screening with or lacking depression cure had no influence on quality-adjusted life years or tribulations in ACS patients with no record of depression.

Key Words: Depression Screening, Quality of Life, Acute Coronary Syndrome, Single Center Experience

Citation of article: Saad AA, Rashid MA, Dastgeer S, Iqbal Z, Raza MH, Javaid I. Effects of Depression Screening on Quality of Life after Diagnosis of Acute Coronary Syndrome, Single Center Experience. Med Forum 2022;33(6):97-101.

INTRODUCTION

About 10 percent of patients with ACS suffer medically significant major depression symptoms. Depression doubles the mortality rate in ACS patients due to high treatment costs and poor life quality.

Many associations of professionals recommended screening of depression in patients with ACS, it was preceding the inclusive handling after diagnoses of depression[1,2].

Screening of depression in ACS patients is controversial. Studies showing the effect of depression treatment have registered only the patients who asked for treatment which confines the general idea about the detection of depression[3]. According to our findings, no such series of treatments have been made for the screening of depression symptoms. Some experts are of the view that the recommendations are impulsive till the demonstration of a randomized diagnosis of depression[4,5]. At the same time, heart care treatment and primary care providers are sure to detect depression symptoms in patients of ACS. Screening causausesairment and deficiency of substantiation from randomized trials are the prime reasons cited for delaying execution[6]. The expenses of depression tests are compounded by the unsympathetic biological effects of augmented use of antidepressant prescription by those whose test results are up[7].

The study is based on CONDIACS-QoL (Companion of Depression Interventions after Acute Coronary Syndrome: Quality of Life), a depression diagnoses

[1.] Department of Cardiology, D.G. Khan Medical College and Teaching Hospital, DG Khan.
[2.] Department of Psychology, Govt. Graduate College of Home Economic, Multan.

Correspondence: Dr. Abubakr Ali Saad, Associate Prof Cardiology, D.G. Khan Medical College and Teaching Hospital, DG Khan.
Contact No: 0300-6301326
Email: cardiologistmic@gmail.com

Received: April, 2022
Accepted: May, 2022
Printed: June, 2022

study of 450 cases with ACS from 4 different health heed systems.

Three groups of people with ACS were generalized: (1) with no depression diagnoses, (2) diagnoses with a warning to the PCP, and (3) screening with a warning to the PCP and stipulation of worse depression conduct that formerly were analyses to be effectual in patients with ACS, but not amongst those with depression diagnoses. The study aimed to examine whether depression diagnoses augmented with quality-adjusted life years and days free of depression.

MATERIALS AND METHODS

Among the 3 groups of the single centered randomized controlled trial conducted at DG Khan Medical College & Teaching Hospital, there were the following: (1) methodical depression test with warning of PCPs and stepped-care depression handling based on a patient penchant for those with positive diagnoses results (screen, advise, and delicacy group); (2) organized depression test with PCP warning only (screen and alert group); and (3) customary concern (no screening group). Participants were chosen September 03 2021 to 02 March 2022. The institutional review board permitted the study,dated 24th August 2021 (Copy attached). Each member signed a consent form. After being randomized, those who were assigned to the screen warn, and cure group were asked to endow within black and white assent.

An age of 21 or more was suggested for the patients with ACS speaking Urdu, Saraiki, Punjabi, Baloch, and Pashtu. Patients were enrolled on the bases of the International Classification of Diseases, Ninth Revision, or international statistical classification of disease regarding Health disorders, 10th Revision, discharge code for severe cardiovascular disease, with a 2 to the 12-month history of ACS. Eligibility was testified through clinical reports. Patients with continued clinical treatment of depression, 1 year or low expected life, patients with bipolar diseases, suicide threat, repeated substance abuse, dementia, pregnancy, acute arthritis liver disorders, with frequent clinical visits, advanced cardiovascular diseases, AIDS, and with cancer of any stage were excluded.

Participants were arranged in 1:1:1 proportion in 3 groups. An incorporated hit and miss number generator generated a block randomization assignment inside strata of 3, 6, or 9 erratically elected sizes. Once all basic data had been inserted through the web-based computer algorithm, an unblinded controller could see the randomization assignment. Afterward, unblinded coordinators accomplished depression tests, warnings, and recommendations for healing if instructed by group assignment and the depression diagnoses upshot. Afterward, unblended coordinators completed depression finding, notification, and recommendation to cure if shown by category assignment and the depression screening outcome. All concluded assessments were executed by blinded coordinators conveyed to group allotment.

Intervention and Control Procedures: The 8-item Patient Questionnaire (PHQ-8), a research-grade affirmed, perceptive and precise depression evaluation tool was used to screen patients allotted for screening, forewarn, and deal factions for depression grade. Patients with major depressive symptoms (PHQ-8>10) were alerted by letters of their inflated depressive symptoms by their general practitioner and/or treating healthcare professional. Unblinded site coordinators educated patients about depression possible treatments. Depression therapies were offered first without mandating a medical assessment of severe depression, and even sub-syndrome anxiety and depression have been associated with a higher risk for poor prediction.

Data Collection: After mandatory conditions, the patients fulfilled the consent process, including the basic evaluation and telephone overview. The evaluation comprised on the bases of gender, age, race, ethnicity, education, originality, marital status, job and employment, the 10-Interner for Epidemiologic Studies Depression scale (CESD-10), and also a quality of life measure regarding health (the 12-item short-Form Healthy Survey, version 20). After basic evaluation, telephone calls had been made at 6, 12, and 18 months to follow-up data compilation. Completion of CESD-10, the 12-Item Short-Form Health Survey, Version 2, a list of symptoms evaluating the potentially fatal effects due to depression and cure; and factors evaluating receipt of depression treatment were considered as the priority for a study tour. The patient completed the PHQ-8 after a completion period of 18 months.

Statistical Analysis: Baseline characteristics were measured as means (SD) and percentages through random evaluation to calculate a reasonable assignment. A two-step gate-keeping was used to make the key connection of change in QALYs in 3 groups. 3 groups were compared using an omnibus *F* test through variance analysis and a two-sided *t-test* in pairs for comparison at 5 percent nominal importance if the omnibus *F* Test had a P-value not greater than .05. This process was expected to control group-wise control type-1 error ratio at 5 percent. The gate-keeping process was used to compare depression-free days of 3 groups in the second result study.

An intention to treat faith was in mind for the whole study. Process for calculations of QALYs, CESD-10, and PHQ-8 at every follow-up was evaluated to examine if they come up with the idea of mislaid at hit and miss by using the Little Test. On fulfilling this idea, mislaid facts and figures were treated using several imputations, through point estimate deriving 5 data sets and pooled variance determined by (1) worst result imputation and (2) last study brought forward. These

results were also calculated using the sex-stratified study method.

Exploration study of variability in utility scores all the time was practiced in the process of liner mixed design along with general seize to know interactions among the patients. These designs comprised time and generalization groups as major impact and time-by-group correlation.

Variance in QALY was calculated using the size of the sample that was clinically significant. It was studied that a sample with a strength of 150, having a 5% decline to follow-up would have 80 percent strength for a 2-sided *t-test* at the 5% standard. These results were deducted assuming SD for QALYs of 0.17 expecting occurrence of diagnoses depression of 20% and also assuming net enhancement in QALYs of 0.155 for one and half years for the patients diagnosed with depression who were treated for depression in the test, warning, and cure group.

Analysis was conducted in R, version 3.4.3 (R foundation for statistical computing). Values of P were derived through 2-sided tests, considering findings statistically important at p <.05. Multiple comparisons were avoided for primary and secondary results keeping in view the 2-step gate-keeping process.

RESULTS

Table No.1: Basic characters

Characteristic	**Screen, Notify and Treat Group (n = 150)**	**Screen and Notify Group (n = 150)**	**No Screen Group (n = 150)**
Age	62.1 (11.3)	64.2 (11.7)	63.7 (11.7)
Married	83 (55.3%)	89 (59.3%)	86 (57.3%)
Employed	52 (34.6%)	48 (32%)	56 (37.3%)
PHQ-8 score ≥10	12/150 (8)	10/501 (6.6)	NA
CESD-10 score, mean (SD)	4.9 (5.1)	4.8 (4.8)	4.7 (4.6)
CESD-10 score ≥10	22/150 (14.6)	18/150 (12)	24/150 (16)
SF-12 Mental score, mean (SD)	18.0 (4.2)	20 (4.3)	16 (3.9)
SF-12 Physical score, mean (SD)	13.6 (3.8)	14.0 (3.9)	16 (4.1)

450 patients were found to fulfill the required criteria for depression diagnoses after ACS considering clinical reports. The mean age was calculated to be 65.9 (11.5) years. The people of the 3 groups were almost the same based on demography, depression, or health condition. 150 patients were allowed to screen, notify, and treat the group, 7.7% had been diagnosed with depression (i.e, PHQ-8 score>10), and twenty-eight positive screened cases showed their assent for stepped care intervention, four choose anti-depression medicine, 14 preferred problem-solving treatment while 10 selected both. Out of 150 patients diagnosed and reported faction, (6.6) were detected positive depression results.

Change in QALYs: There mean of the 3 groups was almost the same with an insignificant difference (1) screen, notify and treat, -0.06 [0.20], (2) screen and notify, -0.06[0.02], (3) no screening, -0.06[.18]; P=.98). QALYs decreased normally from the beginning to the end of 18 months. Imputation of mislaid facts and figures showed constant outcomes while performing analyses for sensitivity in worst result imputation and final inspection brought ahead.

Utilities were found steadily declining when examined utility turnout obtained through quality of living standards at all 4 assessments. All three groups showed the same trend. Even no difference was found in all in the whole duration of 18 months while using a mixed design of the study (secondary study).



Figure No.1: Quality-of-Life Utility Score

Change in Depression-Free Days and Depressive Symptoms: The calculation of cumulative mean for 3 groups showed the same results in days without depression as (1) screen, notify and treat, 78.2 [31.0] days, (2) screen and notify, 75.7 [30.7] days, (3) no screening, 79.0[32.0] days'=.63 even in sign if depression in CESD-10 in this duration. The mean (SD) PHQ-8 score at 18 months did not change involving screening, notifying and treating, screening and notifying, and no screening (all 3.69 [4.21]; P=.99). Stratifying analyses by sex revealed nothing distinctive in depression-free days or depressive signs. In follow-up check-ups, no changes had been found in the proportion of people who took anti-depressant drugs or visited a mental health provider.

DISCUSSION

No distinction had been detected in QALYs between cases with ACS who had been assigned to depression

screening and notification having or having no stipulation of increased depression and a control class who suffered depression screening in this 3-group, depression screening randomized clinical study[8]. There's no variation in depressive signs, depression-free days, or cases of diagnostic hazards seen between the three groups. Strong data depicts that depression is a cardio-toxic major danger in individuals with ACS, and so it is linked to the health-related standard of living. Patients diagnosed with depression, for example, have double the risk of angina, triple the risk of observed physical constraints, and nearly triple the risk of a poor standard of life following an ACS[9,10]. Depression was by far the most significant predictor among the several variables contributing to 1-year excellence of life in research of patients with cardiovascular including socio-demographic indicators, the extent of disease, and other factors. Regardless of the risk of depression, our research shows that monitoring patients with ACS for depression frequently rarely results in significant demographic added benefits of enhanced quality of life or depression-free days[11] .

Depression screening may not have improved depression signs or quality of life for several reasons. A minor percentage than anticipated of study participants had positive results for depression during screening. Participants who had a background of depression were deliberately debarred; either no treatment was given for depression currently. Since depression is declining and abating and undertreated, mounting depression evaluation to take in patients with ACS with a background of depression may aid in case-find supplementary patients with ACS who may advance from improved depression cure[12-14] . In the screen, alert, and treat cluster, apropos 25% of those with positive test fallout decreased the better depression care treatment, which may have limited the effectiveness of this screening room. Even in those who started depression cure; those who have been diagnosed with depression through screening may have been less aggravated or interested in treatment, thereby being less betrothed, reducing treatment effectiveness. In terms of the fraction of cases receiving depression treatment in each group after six months, no differences were found. Studying the differences in concentration, rendezvous, devotion, and/or compliance in cases with depression found through screening and those looking for treatment may prove useful in the future[15].

Many expert societies have suggested depression tests suffered through ACS. Depression is generally screened for people with ACS and is related to inferior health effects, a shoddier feature of life, and greater medical treatment expenses, as suggested by advisories. Nevertheless, proved instructions rank the potency of the verification for clinical suggestions, with the high prescription kept for meta-study of general trials. The study shows strong evidence against depression diagnoses in ACS patients. The analysis stresses the importance of further research needed to be re investigated for patients with ACS[16-18].

The study also provides the same result for diagnoses of depression in other contextual aspects. The study measured the impact of a point-of-care electronic promotion encouraging general physicians to find outpatients with osteoarthritis for depression, angst, and twinge, as compared to pain only. This showed no low signs of depression. During the UK Quality and Outcomes Framework, methodical depression diagnoses were economically incentivized in basic care patients with ACS from 2006 to 2013. In total, it is guessed that 976 cases must be tested for a new screening of depression, and 687 people must be tested for a new prescription for an antidepressant. It was ended in the UK as a quality meter due to low outcomes[19].

CONCLUSION

The results of the survey show that primary care did not change the standard of life, days without depression, signs of stress and anxiety, death, or reported damages for the patients facing ACS providing global screening and notification treatment for depression.

Author's Contribution:

Concept & Design of Study:	Abubakr Ali Saad
Drafting:	Munir Ahmed Rashid, Saima Dastgeer
Data Analysis:	Zahid Iqbal, Muhammad Hussan Raza, Imran Javaid
Revisiting Critically:	Abubakr Ali Saad, Munir Ahmed Rashid
Final Approval of version:	Abubakr Ali Saad, Munir Ahmed Rashid

Conflict of Interest: The study has no conflict of interest to declare by any author.

REFERENCES

1. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al; American Heart Association Prevention Committee of the Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research; American Psychiatric Association. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on

Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 2008;118(17):1768-1775.
2. Thombs BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors of acute myocardial infarction. J Gen Int Med 2006;21(1):30-38.
3. Nieuwsma JA, Williams JW Jr, Namdari N, et al. Diagnostic accuracy of screening tests and treatment for post–acute coronary syndrome depression: a systematic review. Ann Int Med 2017;167(10):725-735.
4. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006;27(23): 2763-2774.
5. Lichtman JH, Froelicher ES, Blumenthal JA, et al. American Heart Association Statistics Committee of the Council on Epidemiology and Prevention and the Council on Cardiovascular and Stroke Nursing. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014;129(12):1350-1369.
6. Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA. Depressive symptoms and health-related quality of life: the Heart and Soul Study [see comment]. JAMA 2003;290(2): 215-221.
7. Rutledge T, Vaccarino V, Johnson BD, et al. Depression and cardiovascular health care costs among women with suspected myocardial ischemia: prospective results from the WISE (Women's Ischemia Syndrome Evaluation) Study. J Am Coll Cardiol 2009;53(2):176-183.
8. Ziegelstein RC, Thombs BD, Coyne JC, de Jonge P. Routine screening for depression in patients with coronary heart disease: never mind. J Am Coll Cardiol 2009;54(10):886-890.
9. Thombs BD, de Jonge P, Coyne JC, et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA 2008;300 (18):2161-2171.
10. Thombs BD, Roseman M, Coyne JC, et al. Does evidence support the American Heart Association's recommendation to screen patients for depression in cardiovascular care? an updated systematic review. PLoS One 2013;8(1):e52654.
11. Smolderen KG, Buchanan DM, Amin AA, et al. Real-world lessons from the implementation of a depression screening protocol in acute myocardial infarction patients: implications for the American Heart Association depression screening advisory. Circ Cardiovasc Qual Outcomes 2011;4(3): 283-292.
12. Thombs BD, de Jonge P, Ziegelstein RC. Depression screening in patients with heart disease—reply. JAMA 2009;301(13):1338.
13. Hasnain M, Vieweg WVR, Lesnefsky EJ, Pandurangi AK. Depression screening in patients with coronary heart disease: a critical evaluation of the AHA guidelines. J Psychosom Res 2011; 71(1):6-12.
14. Thombs BD, Ziegelstein RC, Roseman M, Kloda LA, Ioannidis JP. There are no randomized controlled trials that support the United States Preventive Services Task Force Guideline on screening for depression in primary care: a systematic review. BMC Med 2014;12(1):13.
15. Rieckmann N, Kronish IM, Shapiro PA, Whang W, Davidson KW. Serotonin reuptake inhibitor use, depression, and long-term outcomes after an acute coronary syndrome: a prospective cohort study. JAMA Int Med 2013;173(12):1150-1151.
16. Davidson KW, Rieckmann N, Clemow L, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Arch Int Med 2010;170(7):600-608.
17. Davidson KW, Bigger JT, Burg MM, et al. Centralized, stepped, patient preference-based treatment for patients with post-acute coronary syndrome depression: CODIACS vanguard randomized controlled trial. JAMA Int Med 2013; 173(11):997-1004.
18. Moise N, Davidson KW, Cheung YKK, et al. Rationale, design, and baseline data for a multicenter randomized clinical trial comparing depression screening strategies after acute coronary syndrome: the Comparison of Depression Identification after Acute Coronary Syndromes-Quality of Life and Cost Outcomes (CODIACS-QOL) trial. Contemp Clin Trials 2019;84: 105826.
19. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 2004;66(6):802-813.